Keytruda has partnered with Cancer Therapeutics Electric Field Mercadon to develop a clinical partnership for non-small cell lung cancer.

Lung cancer is one of the leading causes of cancer death worldwide, with more deaths each year from colon cancer and breast cancer combined.
non-small cell lung cancer is the most common type of lung cancer, accounting for about 85% of the total lung cancer.
five-year survival rate for patients diagnosed with non-small cell lung cancer in the United States is about 24 percent.
The cancer therapy electric field developed by Novocure uses an electric field modulated to a specific frequency, allowing polar molecules in cell division to move to a specific location in the cell without moving properly, thereby destroying cell division and inhibiting tumor growth.
the cancer treatment electric field does not stimulate or heat the tissue, the damage to healthy cells is minimal, mild to moderate skin irritation is the most common reported side effect.
Cancer Treatment Electric Field is approved in some countries for the treatment of glioblastoma in adult patients, and in the United States for the treatment of mesothelioma.
the mechanism of the action of the cancer treatment electric field (Photo: Novocure.com) In 2018, Reding Pharma and Novocure reached an agreement to obtain an exclusive license for the cancer treatment electric field in Greater China.
Optune, an innovative product based on an electric field for cancer therapy, was awarded the Innovative Medical Device Designation by the National Drug Administration of China (NMPA) last year for the treatment of adult patients (22 years of age or older) with multiple glioblastoma (GBM).
under the agreement, Novocure and Mercadon plan to conduct a phase 2 clinical pilot study that will combine the tumor treatment electric field with Keytruda to treat patients with advanced or metastatic PD-L1-positive NSCLC in the chest cavity.
the study, which enrolls about 66 patients, is expected to begin in the second half of 2020.
objective mitigation rate (ORR) is the main endpoint of the study.
secondary endpoints include total survival, progression-free survival (PFS), progression-free survival at 6 months, 1-year survival rate, mitigation duration, disease control rate and safety at 18 weeks. "We are excited to work with Mercado to extend the lives of the most aggressive tumor patients by developing and promoting the development and promotion of the most invasive tumors," said William Doyle, Executive Chairman of Novocure. "Several preclinical studies have shown the potential to enhance the immune response by combining tumor therapeutic electric fields with anti-PD-1 therapies, thereby improving tumor control."

we look forward to producing clinical data to demonstrate the effectiveness of the tumor treatment electric field in combination with Keytruda, the first line of treatment nSCLC.
" References: Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Treat Tumoring Field With KEYTRUda ® (pembrolizumab) in Non-Small Cell Lung Cancer.